In a patient with recurrent metastatic Hurthle cell carcinoma of the thyroid whose lymph nodes are refractory to radioactive iodine (RAI), is bilateral cervical neck dissection the only curative surgical option, given that an open (incisional) biopsy is contraindicated?

Bilateral Cervical Neck Dissection for RAI-Refractory Hurthle Cell Carcinoma

Therapeutic neck dissection targeting all confirmed metastatic lymph nodes is the appropriate surgical approach for RAI-refractory Hurthle cell carcinoma with proven nodal metastases, but the extent should be tailored to the specific distribution of disease rather than automatically performing bilateral comprehensive dissection.

Key Surgical Principles

The 2022 French consensus guidelines are explicit that prophylactic neck dissection is NOT indicated for oncocytic (Hurthle cell) carcinoma 1, 2. This is a critical distinction—Hurthle cell carcinoma behaves differently from papillary thyroid cancer, and the surgical approach must reflect this.

Therapeutic vs. Prophylactic Dissection

• Therapeutic neck dissection removes lymph nodes confirmed metastatic preoperatively (via ultrasound and FNAB) or intraoperatively 1
• The goal is removal of all malignant tissue, but dissection should target only compartments with proven disease 1
• Bilateral dissection is NOT automatically indicated simply because disease is present—it depends on the actual distribution of metastases

Extent of Dissection Based on Disease Location

For central compartment involvement (Level VI):

• Ipsilateral central neck dissection when metastatic lymphadenopathy is demonstrated 1, 2
• Contralateral central dissection may be discussed but is not automatic 1

For lateral compartment involvement:

• Dissection of affected compartments (typically Levels III-IV) when proven metastatic 1
• Can be limited to involved sectors if ultrasound shows no suspicious nodes in other lateral sectors 1
• Levels IIA/IIB added only if proven metastatic (not prophylactically, due to accessory spinal nerve palsy risk) 1

Bilateral dissection considerations:

• Insufficient evidence supports routine contralateral prophylactic dissection 1
• May be discussed for high-risk features: bilateral tumors, >3cm ipsilateral lymphadenopathy, or >4 metastatic central nodes 1

The "Only Curative Option" Question

This statement requires nuance. While surgery is the primary curative modality for resectable disease, calling it the "only" option oversimplifies the reality:

Surgery is appropriate when:

• Lymph nodes are confirmed metastatic and surgically accessible
• Disease is limited to resectable compartments
• Patient can tolerate the procedure

However, recognize that:

• Hurthle cell carcinoma has high locoregional recurrence rates despite aggressive surgery 3, 4
• RAI-refractory metastatic disease often requires multimodal management 5, 6
• For progressive or symptomatic disease, systemic therapy (lenvatinib, cabozantinib) may be necessary 5, 7
• Locoregional therapies (stereotactic radiotherapy, thermoablation) can address specific lesions 6

Open Biopsy Contraindication

This is correct. Incisional biopsy of suspected thyroid cancer lymph nodes is contraindicated because:

• It violates tissue planes and increases surgical complexity
• Risk of tumor seeding
• Preoperative diagnosis should be via FNAB with thyroglobulin assay 1
• Intraoperative frozen section can be used for macroscopically suspicious nodes 1

Practical Algorithm for This Patient

1. Preoperative mapping: High-quality ultrasound by experienced practitioner documenting all suspicious nodes with FNAB confirmation 1

2. Surgical planning:

   • Dissect all compartments with proven metastatic disease
   • Do NOT perform prophylactic dissection of uninvolved compartments
   • If bilateral disease is proven, bilateral dissection is appropriate
   • If only unilateral disease, unilateral dissection unless high-risk features present

3. Intraoperative assessment: Frozen section for macroscopically suspicious nodes can guide extent 1

4. Accept surgical limitations: Neck dissection carries risks (hypoparathyroidism, lymphorrhea, nerve injury) that must be balanced against benefit 1

Critical Pitfalls to Avoid

• Do not perform bilateral comprehensive dissection reflexively—this increases morbidity without proven oncologic benefit in Hurthle cell carcinoma 1, 2
• Do not assume surgery alone is curative—Hurthle cell carcinoma has aggressive biology and high recurrence rates 3, 8, 4
• Do not delay consideration of systemic therapy if disease is progressive or symptomatic 5, 7
• Do not perform open biopsy—use FNAB for diagnosis 1

The evidence strongly supports targeted therapeutic dissection of involved compartments rather than routine bilateral comprehensive dissection, with recognition that Hurthle cell carcinoma often requires multimodal management beyond surgery alone.